|
Diversified
Biological Signaling Solutions, Inc. (DBS /DiversifedBio) is an
authorized distributor of Utah Cord Bank (UCB) products, StemVive and Stemii. Please see communication from Customer Service Department and CEO letter. This communication is in response to the news coverage on “Stem Cells” and Liveyon product recall.
In light of the most recent Liveyon (competitor) news
coverage, UCB would like to clarify an assure you of the following.
Please see our attached CEO's letter.
Many of our competitors who sell birth derived allograft
products are venture capitalist groups, some foreign owned, who hire
third party labs that purchase specimens from organ procurement
organizations. These labs rely on birth materials from other states,
and sometimes even from outside American borders. Donor Eligibility
requirements outside of this country often times do not meet U.S.
equivalent standards. When these labs ship the materials between
multiple states, they have substantially longer transit times to the
lab. This has been shown to reduce cellular viability and increase
potential for bacterial contamination.
Please rest assured Utah Cord Bank (UCB) has been in the
cord blood banking and procurement industry for 15 years with a spotless
record. UCB is owned and operated by a husband and wife team that
includes the founding PhD of the company. They and their close staff
personally recover specimens from local Utah hospitals. Donors are
pre-screened for all relevant pathogen criteria and we even screen for
high-risk lifestyles that can negatively influence cellular quality.
Average transit time from hospital to lab is 20 minutes, and
average time from C-section birth to final product is 4 hours. The
chain of custody involves less than 5 people. Additionally, the founding
PhD is involved in every step of the recovery, processing and shipping
of products. He personally developed the proprietary technology that
enables the halting of apoptosis and maximizes cellular viability
post-thaw. In addition to viral testing over and above FDA standards,
all UCB products are quarantined for two weeks after processing until a
complete aerobic bacterial assay is completed (something Liveyon did not
do). Only after stringent testing is completed are our products
released for patient use.
Several of our competitors have received 483 citation
notices from the FDA for deviations. When patient safety, cellular
viability, and product quality are of the utmost importance, know that
UCB leads the industry.
|
|